Riskpilot← Back to searchSign inGet full accessPINDSLE APOTEK AS
ASActiveOrg 991330852Nygårdsveien 84, 3221 SandefjordRetail sale of pharmaceutical products · NACE 4773Est. 20070 employeeswww.pindsleapotek.no
Revenue 2024
NOK 52,6M
+12% vs 2023
EBITDA margin
2.9%
+73% vs 2023
Equity ratio
23.1%
Financial strength
Net profit 2024
NOK 905K
+173% vs 2023
| Revenue | NOK 52,6M | +12% |
| EBITDA | NOK 1,5M | +73% |
| Net profit | NOK 905K | +173% |
| Total assets | NOK 9,4M | -26% |
| Equity | NOK 2,2M | +0% |
| Employees | 0 | — |
Legal name
PINDSLE APOTEK AS
Org number
991330852
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
20. juni 2007
Share capital
NOK 133 330
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og daglig leder hver for seg.
Company purpose
Apotekvirksomhet.
Address
Nygårdsveien 84, 3221 Sandefjord
Website
www.pindsleapotek.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 37 265 | 40 886 | 43 672 | 47 027 | 52 626 |
| Staff expenses | −6 935 | −6 614 | −7 848 | −8 523 | −8 788 |
| EBITDA | 1 381 | 2 564 | 1 406 | 869 | 1 501 |
| Depreciation & amort. | −232 | −438 | −472 | −465 | −460 |
| EBIT | 1 149 | 2 127 | 934 | 404 | 1 041 |
| Net financials | 39 | 24 | 23 | 21 | 119 |
| Profit before tax | 1 188 | 2 150 | 957 | 425 | 1 160 |
| Tax | 261 | 474 | 212 | 93 | 255 |
| Net profit | 927 | 1 677 | 746 | 332 | 905 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 8 802 | 10 375 | 9 567 | 12 718 | 9 408 |
| Equity | 2 157 | 2 167 | 2 179 | 2 178 | 2 176 |
| Long-term debt | 1 406 | 1 140 | 837 | 510 | 144 |
| Short-term debt | 5 239 | 7 068 | 6 551 | 10 031 | 7 087 |
| Total debt | 6 645 | 8 208 | 7 388 | 10 540 | 7 231 |
EBITDA margin
2.9%
This company
15.8%
Market median
-82% vs market
20202024
Equity ratio
23.1%
This company
38.2%
Market median
-40% vs market
20202024
Return on equity
41.6%
This company
18.4%
Market median
+126% vs market
20202024
Net profit margin
1.7%
This company
8.1%
Market median
-79% vs market
20202024
Asset turnover
5.59×
This company
1.12×
Market median
+399% vs market
20202024
Debt / equity
3.32×
This company
0.62×
Market median
-435% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AS Chief Executive Officer | Chief Executive Officer | 2015 |
GO Deputy Member | Deputy Member | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2020 | |
| Board of Directors | 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 75% | 75% | 2024 | |
| Company | 25% | 25% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Mckesson Norway Holding As
PINDSLE APOTEK AS Board members of PINDSLE APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Andrzej Skrzypiec | Chief Executive Officer | 0 companies |
| Garm Oscar Lyckander | Deputy Member | 0 companies |
| Bror-Lennart Mentzoni | Chairman | 0 companies |
| Johan Fredrik Balstad | Board of Directors | 0 companies |